The American Society for Radiation Oncology (ASTRO) has elected three new officers to the Board of Directors and three members to serve on the Nominating Committee. Terms for all positions begin on October 20, 2015 at ASTRO’s 57th Annual Meeting. The new officers to the Board of Directors are:
President-Elect: Brian D. Kavanagh, MD, MPH, FASTRO
Dr. Kavanagh is Professor and Interim Chair of the Department of Radiation Oncology at the University of Colorado School of Medicine, Denver, and an attending physician at the University of Colorado Hospital. His service to ASTRO includes his current roles as Co-Chair of the Health Policy Committee and as the ASTRO Advisor to the American Medical Association/Specialty Society RVS Update Committee. He is currently Co-Director of the ASTRO-AANS Stereotactic Radiosurgery Registry, and he has served ASTRO as a member of the Board of Directors (2011–2015) and in multiple other leadership positions. His additional service has included the Center for Medicare and Medicaid Services’ Hospital Outpatient Payment Advisory Panel and the Ambulatory Payment Classification Advisory Panel, as well as a member of the National Comprehensive Cancer Network’s (NCCN) Policy Advisory Group.
Health Policy Council Vice-Chair: Michael R. Kuettel, MD, PhD, MBA, FASTRO
Dr. Kuettel is Professor and Chair of the Department of Radiation Medicine and The Barbara C. and George H. Hyde Chair in Radiation Medicine at Roswell Park Cancer Institute and State University of New York at Buffalo; he is Professor, Department of Molecular and Cellular Biophysics at Roswell Park Cancer Institute. Dr. Kuettel is Clinical Director of Radiation Oncology at Kaleida Health System. His service to ASTRO includes his current roles as Co-Chair of the Health Policy Committee and as the ASTRO Advisor to the American Medical Association/Specialty Society RVS Update Committee.
Science Council Vice-Chair: Daniel Low, PhD
Dr. Low is Professor in Radiation Oncology and Vice-Chair of Medical Physics in the Department of Radiation Oncology at the University of California, Los Angeles. He currently serves ASTRO as a member of the Funding Advocacy and Clinical Trials Committee, the Best Practices Subcommittee, and the Multidisciplinary Quality Assurance Subcommittee.
The new Nominating Committee members are Quynh-Thu Le, MD, FASTRO, Stanford University; John W. Rieke, MD, MultiCare Regional Cancer Center; and Indrin J. Chetty, PhD, MS, Henry Ford Health System. ■